In Denmark, another medical study on plasma exchange was conducted. A group of experts as headed by Martin Tepel, MD pointed out a diarrhea-associated disease known as hemolytic uremic syndrome (HUS) could be treated by human plasma (the yellow component of blood).
What is Hemolytic Uremic Syndrome?
The HUS is a rare and fatal complication characterized by renal insufficiency, thrombocytopenia and acute hemolytic anemia. Tepel study reveals there were only 0.5-2.1 cases per one hundred thousand people. HUS, moreover, affected more children (6.1 cases per 100,000) younger than five years of age.
As part of the study, Tepel and his group came up with a possible treatment. They tried to use process of plasma exchange yet its benefits remain controversial. The treatment procedure was popularly known as plasmapheresis and the procedure was performed to four women and one man. These patients were around 44-70 years of age, visited the northern part of Germany and it’s confirmed they showed symptoms of HUS associated with E coli (rod-shaped bacterium).
Each patient was treatment with “plasma exchange by centrifugation and substitution with fresh frozen plasma.” This treatment was done every day and luckily, their neurological condition improved. The counts and rates of their median platelet and glomerular filtration rise.
The study also showed a significant relationship between the time of therapy and how quick the treatment took effect. The group concluded early plasma exchange could only improve the course of HUS in adults. These findings, however, needed verifications through randomized controlled trials.
The early treatment proved to be more effective when it’s mixed with carbapenems or antimicrobials. It might also stop the growth of enterocolitis. Presently, the conclusions stood right and symptoms of HUS remained treatable if early plasmapheresis with or without eculizumab was performed.